Intravesical Therapies in Non-muscle Invasive Bladder Tumors
Journal Title: Üroonkoloji Bülteni - Year 2019, Vol 18, Issue 1
Abstract
In the European Association of Urology (EAU) 2015 Guidelines for non-muscle invasive bladder tumors, maintenance Bacillus Calmette-Guérin (BCG) therapy is a grade A recommendation. In the intermediate-risk group, re-evaluation is recommended after 1-year full-dose treatment; in the highrisk group, full-dose BCG is recommended for 1-3 years. Intravesical BCG therapy fails in 40% patients in an average of 2 years. In these cases, there is no alternative treatment that is considered effective. In patients with failed BCG, comparison of BCG and gemcitabine showed less recurrence in the long term with gemcitabine while progression and toxicity were similar. Early radical cystectomy should be considered in non-muscle invasive bladder cancer patients with BCG-refractory T1G3 who have good performance status and low comorbidity. In T1 tumors, invade deeper than 3 mm and/or larger than 6 mm in diameter has been associated with a 100% progression rate. BCG decreased recurrence more significantly in high-risk Ta and T1 tumors. In terms of progression of high-risk superficial bladder cancer, comparison of mitomycin C and BCG showed that BCG is superior if maintenance therapy is given. EAU guidelines recommend early bladder chemotherapy instillation (EBCI), in the low-to-intermediate risk group. There was no clear effect of EBCI in the intermediate- and high-risk group. EBCI alone reduces recurrence only in the low-risk group. However, adjuvant intravesical chemotherapy (AIVC) is recommended in the intermediate- and high-risk groups because it improves relapse-free survival. BCG and maintenance BCG therapy were found to be more effective than AIVC in reducing progression and preventing recurrence.
Authors and Affiliations
Serdar Geyik
Keywords
Related Articles
- EP ID EP550869
- DOI 10.4274/uob.galenos.2018.1116
- Views 101
- Downloads 0
Evaluation of the Side Effect Profile of Intracavitary Bacillus Calmette-Guérin Treatment in Non-muscle-invasive Bladder Cancer
Objective: To reveal the association of side effect profiles seen in patients receiving intravesical bacillus Calmette-Guérin (BCG) immunotherapy for non-muscle-invasive bladder cancer (NMIBC) treatment with patient age...
A Rare Case of Granulomatous Hepatitis After Intravesical BCG Treatment
Tumor recurrence following transurethral resection is common in non-muscle invasive urothelial cancers of the bladder. Intravesical Bacillus Calmette-Guerin (BCG) is frequently used in urology practice to prevent this re...
Risk Factors for Adrenal Invasion in Renal Cell Carcinoma
Objective: In this study, we aimed to describe the risk factors associated with adrenal invasion in patients who were diagnosed with renal cell carcinoma (RCC) after radical nephrectomy and identify which risk factors ar...
The Optimum Dosage of Prilocaine in Periprostatic Nerve Block During Transrectal Ultrasound Guided Prostate Biopsy: A New Approach in Dose Calculation
Objective: We aimed to calculate the optimum dose of prilocaine per one mL prostate volume in periprostatic nerve block (PPNB) during transrectal ultrasound (TRUS) guided prostate biopsy (PBx). Materials and Methods: We...
Active Surveillance in Prostate Cancer
With the widespread use of the prostate specific antigen and prostate biopsies there has been dramatic increase in the incidence of clinically localized prostate cancer. Although there is no consensus about the treatment...